<div id="referencecontent" class="slide1">
	<h1>SPAF References library</h1>
	  <div class="wrapper">
		  <ul class="references scroller" id="references_scroller">
		    <li>
			<a href="javascript:openPDF('docs/Ref01_Di_Carlo-Humanandeconomicburdenofstroke.pdf');"><span>1.</span>
				Di Carlo A. Human and economic burden of stroke. Age Ageing. 2009;38(1):4-5. </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref02_Kannel-PrevalenceincidencePrognosis.pdf');"><span>2.</span>
			  Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation:
			  population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N. </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref03_Marinietal-ContributionofAtrialFibrillationtoIncidenceandOutcomeofIschemicStroke.pdf');"><span>3.</span>
			  Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke.
			  2005;36(6):1115-1119.</a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref04_Gladstone-PotentiallyPreventableStrokesinHigh-RiskPatientsWithAtrialFibrillation.pdf');"><span>4.</span>
			   Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref05_Warfarin_SPC.pdf');"><span>5.</span>
				Warfarin [summary of product
				characteristics]. Frimley, Camberley, Surrey, United Kingdom: Sandoz Ltd; October 2010. </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref06_Waldo-HospitalizedPatientsWithAtrialFibrillationandaHighRiskofStroke.pdf');"><span>6.</span>
			 Waldo AL, Becker RC, Tapson VF, et al; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736.
			 </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
			   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref08_Perzborn-Thediscoveryanddevelopmentofrivaroxaban.pdf');"><span>8.</span>
	         Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2010;10(1):61-75.
			</a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref09_Perzborn-Invitroandinvivostudiesofthenovelantithromboticagent.pdf');"><span>9.</span>
			 Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic
			   agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-521. </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref10_Weitz-Newanticoagulants.pdf');"><span>10.</span>
			   Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3(8):1843-1853.</a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
			  The Executive Steering Committee, on
			  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
			  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
			</li>
			<li class="none">
			 <span>12.</span>
			  Data on file. Bayer HealthCare AG, Berlin, Germany.
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref13_Hacke-BaselinecharacteristicsofROCKETAFstudy.pdf');"><span>13.</span>
			  Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent
			  atrial fibrillation studies. Abstract OAID 5 presented at the 19th European Stroke Conference (ESC); May 25-28, 2010: Barcelona, Spain 2010.
			  </a>
			</li>
			<li>
			<a href="javascript:openPDF('docs/Ref14_EuropeanHeartRhythmAssociation.pdf');"><span>14.</span>
			 European Heart Rhythm Association; Heart Rhythm Society, Fuster V, et al. ACC/AHA/
			 ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of
			 Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906. 
			  </a>
			</li>
			<li>
			 <a href="javascript:openPDF('docs/Ref15_Kubitza-Safetypharmacodynamics.pdf');"><span>15.</span>
			  Kubitza D, Becka M, Wensing G,
			  et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.</a>
			</li>
		</ul>
	</div>
</div>
